Literature DB >> 29375988

IgG4 and IgE co-positive group found in idiopathic orbital inflammatory disease.

Peng-Xiang Zhao1, Yao Mawulikplimi Adzavon1, Jian-Min Ma2, Lei Shang1, Dan-Ying Chen3, Fei Xie1, Meng-Yu Liu1, Xin Zhang1, Bao-Bei Lyu1, Ming-Zi Zhang4, Lin-Qi Yang1, Xue-Mei Ma1.   

Abstract

AIM: To reveal the cytokines involved in idiopathic orbital inflammatory disease (IOID) and the relationship between Th17 cells, IgE and IOID pathogenesis.
METHODS: Whole blood samples were processed immediately after collection and serological IgG4, IgG, and IgE antibodies were tested using ELISA. IOID and orbital cavernous hemangioma (CH) tissue samples underwent Bio-Plex multiplex cytokine detection. Hematoxylin-Eosin (HE) staining of all paraffin samples suggested the histological features of IOIDs, and expressions of IgG4 and IL-17A in affected tissues were detected by immunohistochemistry.
RESULTS: Among 40 IOID plasma samples, 52.5% (21/40) were positive for IgG4 and 25% (10/40) were positive for IgE. Overlapped IgG4 or IgE positive samples accounted for 22.5% (9/40). Therefore, IOID samples were separated into three groups. The IgE+/IgG4+ group had a relevantly lower level of pro-inflammatory cytokine expression. IL-4 (Th2 cell related), IL-10 and TGF-β1 (Treg cell immunity related) were elevated in all three groups. Some of the Th17 cell related cytokines (i.e. IL-17A/F, IL-25, IL-23, and IL-33) displayed higher expression levels in the IgE-/IgG4- group compared to the other two groups.
CONCLUSION: We discovered an IgG4-IgE co-positive group as well as Th17 cell immune involvement in IgG4-IgE co-negative subgtroup in IOID for the first time. The pathogenesis of IOID could differ from different subgroups according to the IgG4 and IgE detection. Therefore, we recommend that, Treatment stratagy should be made according to the clinical assessment of IgG4-IgE and Th17 profile detection.

Entities:  

Keywords:  IgE; IgG4; Th17; idiopathic orbital inflammatory disease

Year:  2018        PMID: 29375988      PMCID: PMC5767655          DOI: 10.18240/ijo.2018.01.07

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  17 in total

Review 1.  Immunoglobulin E: importance in parasitic infections and hypersensitivity responses.

Authors:  W E Winter; N S Hardt; S Fuhrman
Journal:  Arch Pathol Lab Med       Date:  2000-09       Impact factor: 5.534

Review 2.  A clinical overview of IgG4-related systemic disease.

Authors:  Arezou Khosroshahi; John H Stone
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

Review 3.  IL-17 and Th17 Cells.

Authors:  Thomas Korn; Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

Review 4.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

5.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.

Authors:  Marc Massanari; Harold Nelson; Thomas Casale; William Busse; Farid Kianifard; Gregory P Geba; Robert K Zeldin
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

7.  Allergic manifestations in autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Hajime Anjiki; Naoto Egawa; Naoko Kubota
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 2.566

8.  Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium.

Authors:  P Hagan; U J Blumenthal; D Dunn; A J Simpson; H A Wilkins
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

Review 9.  IgG4-related kidney disease.

Authors:  Takako Saeki; Mitsuhiro Kawano
Journal:  Kidney Int       Date:  2013-10-09       Impact factor: 10.612

10.  Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease.

Authors:  Yasufumi Masaki; Nozomu Kurose; Motohisa Yamamoto; Hiroki Takahashi; Takako Saeki; Atsushi Azumi; Shinji Nakada; Shoko Matsui; Tomoki Origuchi; Susumu Nishiyama; Kazunori Yamada; Mitsuhiro Kawano; Akira Hirabayashi; Keita Fujikawa; Tomoko Sugiura; Masanobu Horikoshi; Naoto Umeda; Hiroshi Minato; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Takafumi Kawanami; Yoshimasa Fujita; Masao Tanaka; Toshihiro Fukushima; Katumi Eguchi; Susumu Sugai; Hisanori Umehara
Journal:  Int J Rheumatol       Date:  2012-05-10
View more
  2 in total

1.  Differential Tissue Metabolic Signatures in IgG4-Related Ophthalmic Disease and Orbital Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Hiroyuki Shimizu; Yoshihiko Usui; Ryo Wakita; Yasuko Aita; Atsumi Tomita; Kinya Tsubota; Masaki Asakage; Naoya Nezu; Hiroyuki Komatsu; Kazuhiko Umazume; Masahiro Sugimoto; Hiroshi Goto
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

2.  Expression and Correlation of IgG4 and IL-21 in Collagen-Induced Arthritis Rats.

Authors:  Zhen-Yi Long; Yi-Feng Zhou; Hao Yuan; Ya-Meng Peng; Si-Xian Wu; Fang Peng
Journal:  J Inflamm Res       Date:  2021-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.